Tissue specific mechanism of FXR in suppressing bile-acid synthesis
Tissue specific mechanism of FXR in suppressing bile-acid synthesis
批准号:
8568296
负责人:
GRACE L GUO
金额:
$4.12万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-10 至 2013-05-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Bile acids are mainly produced in the liver with cholesterol 7a hydroxylase (cyp7a1) the rate-limiting enzyme. Bile acids are involved in liver, biliary, intestinal, and cardiovascular diseases. FXR is a bile-acid activated nuclear receptor and is essential in maintaining bile-acid homeostasis. FXR dysfunction contributes to the development of cholestasis, gallstones, fatty-liver disease, and liver tumor. Emerging evidence suggest that in mice FXR suppresses cyp7a1 gene expression via pathways initiated both in the liver and the intestine. However, to understand the roles of FXR in suppressing bile-acid synthesis, clear gaps exist in consolidating where the suppressive pathway initiates, to what extent SHP and FGF15 are involved, and what signaling molecules are in the liver to suppress cyp7a1 gene expression. The objective of this application is to establish the underlying molecular mechanism by which FXR regulates bile-acid synthesis in a tissue-specific manner. My hypothesis is that intestine-initiated FGF15- FGR4 pathway is the major and the liver-initiated SHP-LRH-1 cascade is a minor underlying mechanism for suppressing cyp7a1 with FXR activation, in addition, both Egr-1 and cJun are involved in FGFR4 pathway to suppress cyp7a1 gene expression. The hypothesis is based on our compelling preliminary data that collectively showed that FXR, but not SHP, intestinal FXR, but not hepatic FXR, is mainly responsible for the suppression of cyp7a1 gene expression. We plan to test the hypothesis and accomplish the objective by pursuing the following specific aims. (1) Establish the tissue-specific function of FXR in suppressing cyp7a1 gene expression. (2) Determine to what extent that SHP and FGF15 are involved in suppressing cyp7a1 and regulating bile-acid homeostasis. (3) Elucidate the signaling pathways for suppressing cyp7a1 gene expression following FGFR4 activation. The proposed research is innovative and represents a paradigm shift in understanding the regulation of bile-acid synthesis. We are the first to combine the usage of tissue-specific FXR KO mice with cellular and molecular techniques to identify the fundamental pathways in regulating bile-acid feedback inhibition. These studies will identify the tissue specific roles of FXR, which will provide a fundamental understanding for the study of bile-acid, cholesterol, and triglyceride homeostasis. Furthermore, completion of the proposed study will shed light on designing tissue-specific FXR modulators in the future to better prevent and treat human diseases associated with bile-acid disorders. Public Health Relevance: Bile acids are the main components in bile and are important for regulating cholesterol and triglyceride homeostasis. FXR is essential in regulating bile-acid homeostasis, and contributes to the development of cholestasis, gallstones, fatty-liver disease, liver tumors, and atherosclerosis. Completion of the proposed study will shed light on designing tissue-specific FXR modulators in the future to better prevent and treat human diseases associated with bile-acid disorders.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.phrs.2010.12.018
发表时间:
2011-04
期刊:
PHARMACOLOGICAL RESEARCH
影响因子:
9.3
作者:
[Zhu, Yan, Li, Fei, Guo, Grace L.]
通讯作者:
Guo, Grace L.
DOI:
10.1016/j.apsb.2016.07.008
发表时间:
2016-09
期刊:
ACTA PHARMACEUTICA SINICA B
影响因子:
14.5
作者:
[Zhu, Yan, Liu, Hongxia, Zhang, Min, Guo, Grace L.]
通讯作者:
Guo, Grace L.
DOI:
10.1371/journal.pone.0085890
发表时间:
2014
期刊:
PloS one
影响因子:
3.7
作者:
[Kong B, Guo GL]
通讯作者:
Guo GL
Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration.
Farnesoid X 受体,胆汁酸传感核受体,在肝再生中。
DOI:
10.1016/j.apsb.2015.01.005
发表时间:
2015-03
期刊:
Acta pharmaceutica Sinica. B
影响因子:
--
作者:
[Li G, L Guo G]
通讯作者:
L Guo G
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
-
批准号:10207687
-
项目类别:
-
资助金额:$39.76万
-
财政年份:2020
-
负责人:GRACE L GUO
-
依托单位:
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
-
批准号:10286769
-
项目类别:
-
资助金额:$1.39万
-
财政年份:2020
-
负责人:GRACE L GUO
-
依托单位:
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
-
批准号:10606597
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2020
-
负责人:GRACE L GUO
-
依托单位:
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
-
批准号:10386929
-
项目类别:
-
资助金额:$31.4万
-
财政年份:2020
-
负责人:GRACE L GUO
-
依托单位:
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
-
批准号:10601255
-
项目类别:
-
资助金额:$7.0万
-
财政年份:2020
-
负责人:GRACE L GUO
-
依托单位:
Role of Intestinal Bile Acid Signaling in Liver Diseases
-
批准号:10621137
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:GRACE L GUO
-
依托单位:
Role of Intestinal Bile Acid Signaling in Liver Diseases
-
批准号:10257976
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:GRACE L GUO
-
依托单位:
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis
-
批准号:8421637
-
项目类别:
-
资助金额:$30.04万
-
财政年份:2013
-
负责人:GRACE L GUO
-
依托单位:
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis
-
批准号:8697069
-
项目类别:
-
资助金额:$28.24万
-
财政年份:2013
-
负责人:GRACE L GUO
-
依托单位:
Gut bile acids, Fxr, & Fgf15 in total parenteral nutrition-associated cholestasis
-
批准号:9066738
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2013
-
负责人:GRACE L GUO
-
依托单位:
FXR, nuclear receptors, and transcriptional regulation of liver homeostasis
-
批准号:8328025
-
项目类别:
-
资助金额:$32.84万
-
财政年份:2011
-
负责人:GRACE L GUO
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: NULL-MOUSE CORE
-
批准号:8360781
-
项目类别:
-
资助金额:$3.33万
-
财政年份:2011
-
负责人:GRACE L GUO
-
依托单位:
Tissue specific mechanism of FXR in suppressing bile-acid synthesis
-
批准号:8012056
-
项目类别:
-
资助金额:$9.98万
-
财政年份:2010
-
负责人:GRACE L GUO
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: NULL-MOUSE CORE
-
批准号:8167660
-
项目类别:
-
资助金额:$3.12万
-
财政年份:2010
-
负责人:GRACE L GUO
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE
-
批准号:7959504
-
项目类别:
-
资助金额:$3.92万
-
财政年份:2009
-
负责人:GRACE L GUO
-
依托单位:
FXR ALTERS HEPATIC LIPID METABOLISM & DECREASES FATTY LIVER DEVELOPMENT
-
批准号:7720184
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2008
-
负责人:GRACE L GUO
-
依托单位:
Tissue specific mechanism of FXR in suppressing bile-acid synthesis
-
批准号:7867915
-
项目类别:
-
资助金额:$31.15万
-
财政年份:2008
-
负责人:GRACE L GUO
-
依托单位:
Tissue specific mechanism of FXR in suppressing bile-acid synthesis
-
批准号:8106415
-
项目类别:
-
资助金额:$26.49万
-
财政年份:2008
-
负责人:GRACE L GUO
-
依托单位:
COBRE: U OF KANSAS MEDICAL CTR: CORE C: NULL-MOUSE CORE
-
批准号:7720181
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2008
-
负责人:GRACE L GUO
-
依托单位:
Tissue specific mechanism of FXR in suppressing bile-acid synthesis
-
批准号:7633271
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2008
-
负责人:GRACE L GUO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
新生儿坏死性小肠结肠炎中去泛素化酶USP15调控ILC3分化损伤肠道粘膜屏障的致病机制研究
-
批准号:82371711
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:吕志宝
-
依托单位:
人巨细胞病毒编码蛋白UL23调控 HCMV-specific T 细胞增殖、活性及分化的机理
-
批准号:32070149
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:李弘剑
-
依托单位:
花胶鱼类物种Species-specific PCR和Multiplex PCR鉴定体系研究
-
批准号:31902373
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2019
-
负责人:曾玲
-
依托单位:
Dravet综合征基因突变分析及突变来源研究
-
批准号:81171221
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:张月华
-
依托单位:
睾丸特异性新基因TSC29的表达调控机制及其功能研究
-
批准号:81170613
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2011
-
负责人:唐爱发
-
依托单位:
RNA结合蛋白CUG-BP1对于mRNA降解的调控机制研究
-
批准号:31000570
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:张礼斌
-
依托单位:
新生隐球菌减数分裂特异性基因ISC10的生理功能研究
-
批准号:30970130
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2009
-
负责人:潘炜华
-
依托单位:
寻找精神分裂症的调节性遗传变异
-
批准号:30870899
-
项目类别:面上项目
-
资助金额:45.0万元
-
批准年份:2008
-
负责人:David Saffen
-
依托单位: